Autopsy report · NCT02681809

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

“Slow recruitment rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 3 years 11 months before it stopped.
• 48 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

ThromboGenics

Sponsor type

Industry

Conditions

Diabetic Retinopathy; Posterior Vitreous Detachment; Disease Progression

Interventions

ocriplasmin 0.0625mg; ocriplasmin 0.125mg; Sham injection

Participants

48

Sites

38

Countries

Czechia, France, Germany, Hungary, Israel, Italy, Spain, United Kingdom, United States

Trials that died the same way

• Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
  “Recruitment Rate too slow” (96% match in meaning)
• Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
  “Slower than expected recruitment rate” (94% match in meaning)
• Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens
  “recruitment slow” (94% match in meaning)
• Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung
  “Slow recruitment” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.